These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38879065)

  • 1. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays.
    Ashrafzadeh-Kian S; Figdore D; Larson B; Deters R; Abou-Diwan C; Bornhorst J; Algeciras-Schimnich A
    Clin Chim Acta; 2024 Jul; 561():119817. PubMed ID: 38879065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform.
    Lee S; Plavina T; Singh CM; Xiong K; Qiu X; Rudick RA; Calabresi PA; Stevenson L; Graham D; Raitcheva D; Green C; Matias M; Uzgiris AJ
    Front Neurol; 2022; 13():935382. PubMed ID: 35959400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
    Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
    Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Shahim P; Norato G; Sinaii N; Zetterberg H; Blennow K; Chan L; Grunseich C
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.
    Gaiottino J; Norgren N; Dobson R; Topping J; Nissim A; Malaspina A; Bestwick JP; Monsch AU; Regeniter A; Lindberg RL; Kappos L; Leppert D; Petzold A; Giovannoni G; Kuhle J
    PLoS One; 2013; 8(9):e75091. PubMed ID: 24073237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis.
    Verde F; Steinacker P; Weishaupt JH; Kassubek J; Oeckl P; Halbgebauer S; Tumani H; von Arnim CAF; Dorst J; Feneberg E; Mayer B; Müller HP; Gorges M; Rosenbohm A; Volk AE; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):157-164. PubMed ID: 30309882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.
    Gille B; De Schaepdryver M; Goossens J; Dedeene L; De Vocht J; Oldoni E; Goris A; Van Den Bosch L; Depreitere B; Claeys KG; Tournoy J; Van Damme P; Poesen K
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):291-304. PubMed ID: 29908069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.
    Kojima Y; Kasai T; Noto YI; Ohmichi T; Tatebe H; Kitaoji T; Tsuji Y; Kitani-Morii F; Shinomoto M; Allsop D; Teramukai S; Mizuno T; Tokuda T
    PLoS One; 2021; 16(11):e0260323. PubMed ID: 34843548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
    Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
    Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.
    Benatar M; Macklin EA; Malaspina A; Rogers ML; Hornstein E; Lombardi V; Renfrey D; Shepheard S; Magen I; Cohen Y; Granit V; Statland JM; Heckmann JM; Rademakers R; McHutchison CA; Petrucelli L; McMillan CT; Wuu J;
    EBioMedicine; 2024 Oct; 108():105323. PubMed ID: 39270623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.
    Witzel S; Frauhammer F; Steinacker P; Devos D; Pradat PF; Meininger V; Halbgebauer S; Oeckl P; Schuster J; Anders S; Dorst J; Otto M; Ludolph AC
    Transl Neurodegener; 2021 Aug; 10(1):31. PubMed ID: 34433481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid and blood neurofilament light chain levels in amyotrophic lateral sclerosis and frontotemporal degeneration: A meta-analysis.
    Verde F; Licaj S; Soranna D; Ticozzi N; Silani V; Zambon A
    Eur J Neurol; 2024 Sep; 31(9):e16371. PubMed ID: 38937912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
    Benatar M; Zhang L; Wang L; Granit V; Statland J; Barohn R; Swenson A; Ravits J; Jackson C; Burns TM; Trivedi J; Pioro EP; Caress J; Katz J; McCauley JL; Rademakers R; Malaspina A; Ostrow LW; Wuu J;
    Neurology; 2020 Jul; 95(1):e59-e69. PubMed ID: 32385188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
    Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M
    Neurology; 2018 Jan; 90(1):e22-e30. PubMed ID: 29212830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis.
    Nicolella V; Fiorenza M; Monteiro I; Novarella F; Sirica R; D'Angelo M; Carbone G; La Civita E; Esposito A; Criscuolo V; Carotenuto A; Petracca M; Lanzillo R; Castaldo G; Morra VB; Terracciano D; Moccia M
    J Neurol Sci; 2024 Aug; 463():123115. PubMed ID: 38964268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.
    Benatar M; Wuu J; Andersen PM; Lombardi V; Malaspina A
    Ann Neurol; 2018 Jul; 84(1):130-139. PubMed ID: 30014505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.
    Lewczuk P; Ermann N; Andreasson U; Schultheis C; Podhorna J; Spitzer P; Maler JM; Kornhuber J; Blennow K; Zetterberg H
    Alzheimers Res Ther; 2018 Jul; 10(1):71. PubMed ID: 30055655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.